Trial Profile
A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Histamine dihydrochloride (Primary)
- Indications Chronic myelomonocytic leukaemia
- Focus Adverse reactions
- 28 Apr 2017 Status changed from not yet recruiting to recruiting.
- 27 Jul 2016 New trial record